The global biological and chemical indicators market is set to value at US$ 490.3 million in 2023. With an estimated growth rate of 5.9% CAGR during the forecast period, the market is likely to surpass US$ 866.9 million by 2033. The increasing emphasis on patient safety and infection control in the healthcare sector drives the demand for biological and chemical indicators. Some factors driving the market growth include:
| Data Points | Market Insights |
|---|---|
| Market Value 2023 | US$ 490.3 million |
| Market Value 2033 | US$ 866.9 million |
| CAGR 2023 to 2033 | 5.9% |
| Share of Top 5 Countries | 61.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The biological and chemical indicators industry is witnessing several innovations in terms of product development and technological advancements. The development of self-contained biological indicators and the integration of electronic monitoring systems are some of the innovations in this market.
The use of biological indicators in the food and beverage processing industries is also expected to provide significant growth opportunities for players in this market. In addition, the increasing adoption of chemical sterilization methods is expected to drive the demand for chemical indicators, creating opportunities for market players to develop new and innovative products.
The sales of biological and chemical indicators are expected to be driven by the increasing awareness of the importance of sterilization procedures in healthcare facilities. The demand for biological indicators is expected to witness significant growth due to their accuracy and reliability in monitoring the effectiveness of thermal sterilization processes.
The adoption of chemical sterilization methods is also driving the demand for chemical indicators. This market is witnessing several innovations in terms of product development and technological advancements, creating opportunities for players to develop new and innovative products. With the increasing emphasis on patient safety and infection control in the healthcare sector, the biological and chemical indicators industry is expected to witness significant growth during the forecast period.
As projected by Future Market Insights, the biological indicators by indicator class are estimated to see a market value of US$ 393.2 million, which shows more than half of the total biological and chemical indicators industry in 2022.
The increasing adoption rate of universal sterilization indicators, increasing advanced product development, rising commercialization of parenteral therapeutics, diagnosing disease, and development of In-house sterilization monitoring solutions are the primary factors boosting the development of the biological and chemical indicators industry.
The biological and chemical indicators market holds nearly 10.4% of the market value share of the US$ 4.1 billion sterilization market in 2021. In addition, collaborative efforts and initiatives to do efficient workflow and the emerging trend of exploring next-generation techniques are expected to lead to rapid growth in the biological and chemical indicators industry.
| Particulars | Details |
|---|---|
| H1, 2021 | 7.28% |
| H1, 2022 Projected | 7.28% |
| H1, 2022 Outlook | 7.28% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 13 ↓ |
According to FMI, the biological and chemical indicators market is likely to dip in the BPS change by nearly 13 basis point share (BPS) in H1-2022 (O) compared to H1-2021. Furthermore, variation in BPS change is also observed by comparing the H1-2022 outlook and H1-2022 projected period by nearly 10 BPS.
The shortcomings of rapid biological indicators include that under unfavorable conditions such as temperature variation, the period available to detect fluorescence is not adequate, thus presenting with lower output than expected. This factor is associated with several disadvantages to the market.
The underdeveloped regions have limitations regarding the resources and capabilities for sterilization procedures and monitoring, which contributes to the BPS value reduction.
The growth rates and development possibilities of the global biological and chemical indicators industry have been analyzed by FMI. The market is subject to be influenced by quality assessment, regulations, and the impact of macro and industrial variables.
Principal Consultant
The growing risk of infections during surgeries and hospital-acquired infections creates a huge demand for safety and hygiene in the sterile production process. Numerous hygiene awareness programs in various regions to promote the use of sterile instruments and equipment is likely to create opportunities in the biological and chemical indicators industry shortly.
For Instance, the Georgia Environmental Protection Division (EPD) and USA Environmental Protection Agency (EPA) gave joint protocol to provide support by increasing the production at sterilization facilities in Covington and Madison during COVID there was high demand and short supply for sterile medical equipment.
Surgical care is essential to manage diverse health conditions, such as injuries, malignancy, infections, and cardiovascular diseases. An increase in the number of surgical procedures is likely to directly impact the sale of biological and chemical indicators. According to a WHO study, in 2020, around 310 million surgical procedures were used to address the burden of different diseases for the global population.
Inconvenience, long waiting times for results, sub-standard sterilization practices, and increasing adoption of disposable biological and chemical indicators are the key factors restraining the market growth over the forecast period.
The classical sterilization indicators, such as biological indicators, take a longer period, about 7 days, to show results. In addition, chemical indicators can give false positive results and are generally not recommended by healthcare regulatory agencies. This disadvantage of classic sterilization indicators is expected to hamper the adoption rate of the products.
Underdeveloped regions have limited resources and capabilities for sterilization procedures and monitoring. In the non-regulated market, several professionals rely on non-validated sterilization procedures or violate standard sterilization protocols. Such practices are expected to reduce the use of sterilization indicators during sterilization procedures, a major factor restraining the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| United States Market Size (US$ million) by End of Forecast Period (2033) | US$ 169.4 million |
|---|---|
| CAGR % 2023 to End of Forecast (2033) | 4.9% |
The United States biological and chemical indicators industry is expected to reach a valuation of US$ 169.4 million by the end of the forecast period in 2033, with a CAGR of 4.9% between 2023 and 2033.
The dominant share of the United States can mainly be due to the launch of technologically advanced products, regulatory stringency and compliance, and increasing discretionary funding for cancer research. With advancements in manufacturing and digitalization, healthcare professionals expect customized sterilization indicator solutions in sterilization monitoring operations.
Several innovative biological and chemical indicator suppliers in the United States market are offering customized services of sterilization indicators specific to the need of the end users. This driver is expected to provide a competitive edge for the players in the market.
For example, Sterilization Indicators contract manufacturer (OME) and Propper Manufacturing Co., Inc., United States, offer multiple packaging forms and indicators for customization needs to healthcare end users. These include cost-effective, environmentally friendly, tailored to specific customer needs, and maintaining ISO and FDA compliance.
Regulatory authorities of regulated markets such as the United States and ISO regions have issued separate guidelines on the regulatory requirements of the sterilization validation procedures for compliance with the sterilization procedures. This regulatory stringency is expected to increase the demand for biological and chemical indicators across the global and United States market.
| Europe Region Analysis | Value and CAGR |
|---|---|
| Germany Market Size (US$ million) by End of Forecast Period (2033) | US$ 20.7 million |
| CAGR % 2023 to End of Forecast (2033) | 3.7% |
| United Kingdom Market Size (US$ million) by End of Forecast Period (2033) | US$ 19.5 million |
| CAGR % 2023 to End of Forecast (2033) | 6.0% |
In Germany, the biological and chemical indicators market is predicted to reach a valuation of US$ 20.7 million by 2033, with a CAGR of 3.7% from 2023 to 2033. German companies have a strong focus and continuous investments in research and technological advancement for developing and commercializing rapid sterilization monitoring products. These are expected to raise the adoption of biological indicators due to their high speed and high efficacy features.
The United Kingdom biological and chemical indicators market is estimated to be valued at US$ 19.5 million by 2033, with a CAGR of 6.0% during the forecast period.
For instance, Protak Scientific Ltd., a Europe-based innovative startup, invented and commercialized a new class of sterilization indicators known as Enzyme Indicators. The product uses a thermostable Adenylate kinase (tAK) enzyme isolated from thermophilic bacteria found in hot springs (Sulpholobus acidocaldarius).
| China Market Size (US$ million) by End of Forecast Period (2033) | US$ 32.7 million |
|---|---|
| CAGR % 2023 to End of Forecast (2033) | 5.3% |
China's biological and chemical indicators market is projected to attain a value of US$ 32.7 million by the end of the forecast period in 2033, with a CAGR of 5.3% from 2023 to 2033. Increasing community and hospital-acquired infections create opportunities for biological and chemical indicators in the Chinese market.
The biopharmaceutical industry is actively engaged in the development of novel biologics and sensitive products. Among the newly commercialized biologics, the majority of therapeutics are formulated in the parenteral dosage form. This increase in parenteral dosage manufacturing volume across the biopharmaceutical industry is expected to fuel the growth of China's biological and chemical indicators industry.
In 2022, India's demand for biological and chemical indicators was expected to grow at a market share of 72.0%. Outsourcing of biopharma research is done extensively in emerging countries like India. The clinical trial partnership of various key players with emerging companies to speed up the clinical trial process is rising. The partnership is expected to help both companies to achieve the best results in less time. Such partnership agreements amongst players are likely to help gain traction in the Indian market.
| Top Sterilization Type | Thermal Sterilization |
|---|---|
| CAGR % 2023 to End of Forecast (2033) | 6.9% |
By sterilization type, thermal sterilization is anticipated to hold the largest share of 69.4% in 2022. The segment is anticipated to record a CAGR of 6.9% during the forecast period. This is due to a significant preference for steam heat sterilization over other sterilization types owing to a high possibility of toxicity, handling risk, and environmental pollution associated with other sterilization types. Thermal sterilization uses the thermal liability of a microorganism to prevent its growth. Hence growing popularity and demand for this segment make it the leading one.
By indicator class, biological indicators are likely to lead the market and are projected to account for 85.8% of the total market revenue share in 2022.
The biological indicators segment is widely dominated due to regulatory recommendations to use biological indicators instead of chemical ones to achieve a high standard of sterility assurance. In addition, increasing commercialization of user-friendly biological indicators with rapid sterilization validation compliance is a key factor in the rising biological indicators adoption rate.
By form, self-contained BI is anticipated to hold the largest share of 42.0% in 2022. The high flexibility and efficiency of self-contained BI to deliver rapid results and an overall increase in operational efficiency leads this segment to hold the highest share.
| Top End User | Biopharma Industry |
|---|---|
| CAGR % 2023 to End of Forecast (2033) | 4.8% |
By End User, the biopharma industry is anticipated to hold nearly half of the global market share in revenue in 2022. The biopharma industry is anticipated to maintain the lead with a CAGR of 4.8% during the forecast period.
Among all end users, the biopharma industry is a leading segment that hospitals follow. The rising parenteral formulation, including new (biologics/synthetics) and generic formulations and stringent regulatory compliance requirements of sterilization validation, is rising the demand for sterilization indicators in the biopharmaceutical industry.
Companies operating in the biological and chemical indicators industry are naturally fragmented, with few players. These players are involved in several strategic alliances. The agreement and system automation accelerates the manufacturer’s strategy to capitalize on the market share and capture a significant market share.
Innovation is a major driver of growth in the biological and chemical indicators industry, with players continuously investing in research and development to improve their offerings. For instance, STERIS plc recently introduced a new range of chemical indicators that provide accurate and reliable monitoring of sterilization processes. Similarly, 3M Company has developed a unique biological indicator system that can detect the presence of spores in just one hour.
One of the major challenges facing players in the biological and chemical indicators industry is the need for stringent regulatory compliance. Companies need to adhere to various regulatory guidelines to ensure the safety and efficacy of their products. To address this challenge, players invest heavily in quality control and assurance measures to maintain compliance with regulatory standards.
Another challenge facing players in the industry is the increasing competition and pricing pressures. With new players entering the market, existing players need to differentiate themselves by offering unique value propositions and competitive pricing strategies. Companies invest in marketing and branding initiatives to address this challenge to increase brand awareness and market share.
Latest Developments in the Biological and Chemical Indicators Industry:
| Attribute | Details |
|---|---|
| Forecast Period | 2017 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ million for Value |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, Nordic, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC Countries, South Africa, Turkey |
| Key Segments Covered | Sterilization Type, Indicator Class, Packaging Form, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The Biological and Chemical Indicators Market is set to attain a value of US$ 490.3 million in 2023.
The Biological and Chemical Indicators Market is estimated to surpass US$ 866.9 million by 2033.
The Biological and Chemical Indicators Market is projected to experience a CAGR of 5.9% through 2033.
Chinese population growth, rising healthcare costs, sepsis prevalence, and rising PCT assay knowledge all contribute to the country's market expansion.
The need for point-of-care services, the focus on patient safety, and technological advancements all contribute to the market's positive historical performance.
1. Executive Summary | Biological and Chemical Indicators Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sterilization Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Sterilization Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sterilization Type, 2023 to 2033
5.3.1. Thermal Sterilization
5.3.1.1. Steam Heat
5.3.1.2. Dry Heat
5.3.2. Chemical Sterilization
5.3.2.1. Ethylene Oxide
5.3.2.2. Hydrogen Peroxide
5.3.2.3. Formaldehyde
5.3.3. Radiation Sterilization
5.4. Y-o-Y Growth Trend Analysis By Sterilization Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Sterilization Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indicator Class
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Indicator Class, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indicator Class, 2023 to 2033
6.3.1. Biological Indicators
6.3.1.1. Geobacillus stearothermophilus (GS) Spores
6.3.1.2. Bacillus atrophaeus (BA) Spores
6.3.2. Chemical Indicators
6.3.2.1. Class 1 (Process)
6.3.2.2. Class 4 (Multi-Variable)
6.3.2.3. Class 2 (Specific-Use)
6.3.2.4. Class 3 (Single-Variable)
6.3.2.5. Class 5 (Integrating)
6.3.2.6. Class 6 (Cycle Verification)
6.3.3. Enzyme Indicators
6.4. Y-o-Y Growth Trend Analysis By Indicator Class, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Indicator Class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033
7.3.1. Biopharma Industry
7.3.2. Hospital & Clinics
7.3.3. Ambulatory Surgical Centres
7.3.4. Diagnostic Labs
7.3.5. Research Labs
7.4. Y-o-Y Growth Trend Analysis By End User , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Sterilization Type
9.2.3. By Indicator Class
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Sterilization Type
9.3.3. By Indicator Class
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Sterilization Type
10.2.3. By Indicator Class
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Sterilization Type
10.3.3. By Indicator Class
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Sterilization Type
11.2.3. By Indicator Class
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Sterilization Type
11.3.3. By Indicator Class
11.3.4. By End User
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Sterilization Type
12.2.3. By Indicator Class
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Sterilization Type
12.3.3. By Indicator Class
12.3.4. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Sterilization Type
13.2.3. By Indicator Class
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Sterilization Type
13.3.3. By Indicator Class
13.3.4. By End User
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Sterilization Type
14.2.3. By Indicator Class
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Sterilization Type
14.3.3. By Indicator Class
14.3.4. By End User
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Sterilization Type
15.2.3. By Indicator Class
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Sterilization Type
15.3.3. By Indicator Class
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Sterilization Type
16.1.2.2. By Indicator Class
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Sterilization Type
16.2.2.2. By Indicator Class
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Sterilization Type
16.3.2.2. By Indicator Class
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Sterilization Type
16.4.2.2. By Indicator Class
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Sterilization Type
16.5.2.2. By Indicator Class
16.5.2.3. By End User
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Sterilization Type
16.6.2.2. By Indicator Class
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Sterilization Type
16.7.2.2. By Indicator Class
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Sterilization Type
16.8.2.2. By Indicator Class
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Sterilization Type
16.9.2.2. By Indicator Class
16.9.2.3. By End User
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Sterilization Type
16.10.2.2. By Indicator Class
16.10.2.3. By End User
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Sterilization Type
16.11.2.2. By Indicator Class
16.11.2.3. By End User
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Sterilization Type
16.12.2.2. By Indicator Class
16.12.2.3. By End User
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Sterilization Type
16.13.2.2. By Indicator Class
16.13.2.3. By End User
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Sterilization Type
16.14.2.2. By Indicator Class
16.14.2.3. By End User
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Sterilization Type
16.15.2.2. By Indicator Class
16.15.2.3. By End User
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Sterilization Type
16.16.2.2. By Indicator Class
16.16.2.3. By End User
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Sterilization Type
16.17.2.2. By Indicator Class
16.17.2.3. By End User
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Sterilization Type
16.18.2.2. By Indicator Class
16.18.2.3. By End User
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Sterilization Type
16.19.2.2. By Indicator Class
16.19.2.3. By End User
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Sterilization Type
16.20.2.2. By Indicator Class
16.20.2.3. By End User
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Sterilization Type
16.21.2.2. By Indicator Class
16.21.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Sterilization Type
17.3.3. By Indicator Class
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. The 3M Company
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Steris Plc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Thermo Fisher Scientific, Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Mesa Labs, Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. McKesson Medical-Surgical Inc.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Crosstex International, Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Propper Manufacturing Co., Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Terragene S.A.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Andersen Products, Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Getinge AB
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. GKE-GmbH
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Liofilchem S.r.l.
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
18.1.13. Protak Scientific Ltd.
18.1.13.1. Overview
18.1.13.2. Product Portfolio
18.1.13.3. Profitability by Market Segments
18.1.13.4. Sales Footprint
18.1.13.5. Strategy Overview
18.1.13.5.1. Marketing Strategy
18.1.14. ParaSure Limited
18.1.14.1. Overview
18.1.14.2. Product Portfolio
18.1.14.3. Profitability by Market Segments
18.1.14.4. Sales Footprint
18.1.14.5. Strategy Overview
18.1.14.5.1. Marketing Strategy
18.1.15. Excelsior Scientific
18.1.15.1. Overview
18.1.15.2. Product Portfolio
18.1.15.3. Profitability by Market Segments
18.1.15.4. Sales Footprint
18.1.15.5. Strategy Overview
18.1.15.5.1. Marketing Strategy
18.1.16. Siltex Australia Pvt. Ltd.
18.1.16.1. Overview
18.1.16.2. Product Portfolio
18.1.16.3. Profitability by Market Segments
18.1.16.4. Sales Footprint
18.1.16.5. Strategy Overview
18.1.16.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Biological and Chemical Indicators Market
